Cargando…
Serum GFAP as a biomarker for disease severity in multiple sclerosis
While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum o...
Autores principales: | Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., Otto, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172254/ https://www.ncbi.nlm.nih.gov/pubmed/30287870 http://dx.doi.org/10.1038/s41598-018-33158-8 |
Ejemplares similares
-
Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis
por: Abdelhak, A., et al.
Publicado: (2019) -
Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
por: Abdelhak, Ahmed, et al.
Publicado: (2019) -
Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease
por: Huss, André, et al.
Publicado: (2022) -
Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
por: Huss, André, et al.
Publicado: (2020) -
Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity
por: Ayrignac, Xavier, et al.
Publicado: (2020)